Sunday, July 18, 2021

NICE rejects Pfizer’s rare heart disease treatment Vyndaqel




Pfizer’s Vyndaqel has been rejected by the UK National Institute for Health and Care Excellence (NICE) as a treatment for the rare heart condition transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

The final guidance publication comes following an appeal against earlier draft recommendations by Pfizer, Cardiomyopathy UK and the British Society for Heart Failure, NICE said in a statement.

In the UK, around 800 people live with ATTR-CM, a rare, under-diagnosed and life-threatening disease characterised by the buildup of abnormal deposits of misfolded protein called amyloid in the heart.

Once diagnosed, the median life expectancy in patients with ATTR-CM, dependent on sub-type, is approximately two to 3.5 years.

NICE said that cost-effectiveness estimates for Vyndaqel are higher than what would normally be considered an acceptable use of NHS resources.

The agency added that there isn’t enough evidence that a recommendation for Pfizer’s drug would reduce delays in diagnosis, with further uncertainty regarding the long-term benefit of Vyndaqel once treatment is stopped.

NICE said that it ‘remains keen’ to ensure access to Vyndaqel for ATTR-CM patients, adding that it is willing to conduct a rapid review of the final guidance if NHS England and Pfizer can reach an agreement for a new value proposition which may make the drug cost-effective.

In February 2020, Vyndaqel became the first treatment approved in Europe for the treatment of ATTR-CM.

The European Commission based this approval on from the Phase III ATTR-ACT study, the first and only completed global, double-blind, randomised, placebo-controlled clinical trial to investigate a pharmacologic therapy for the treatment of ATTR-CM.

In the study, the drug was shown to reduce the hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalisations compared to placebo.



Source link

Stay Connected

1,605FansLike
11,000FollowersFollow
342FollowersFollow
775FollowersFollow

Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...